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Acute revascularization is associated with improved outcomes in ischemic stroke patients.
It is unclearwhichmethod of intra-arterial intervention, if any, is ideal. Promising approaches
in acute stroke treatment are likely a combination of intravenous and endovascular revas-
cularization efforts, combining early treatment initiation with direct clot manipulation
and/or PTA/stenting. In this review, we will discuss available thrombolytic therapies and
endovascular recanalization techniques, beginning with chemical thrombolytic agents, fol-
lowed by mechanical devices, and a review of ongoing trials. Further randomized studies
comparing medical therapy, intravenous and endovascular treatments are essential, and
their implementation will require the wide support and enthusiasm from the neurologic,
neuroradiologic, and neurosurgical stroke communities.
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INTRODUCTION
The National Institute of Neurological Disorders and Stroke
(NINDS, 1995) trial initiated a new era for recanalization ther-
apies for acute ischemic stroke patients. In 1996, after review of
the results of the NINDS study demonstrating better clinical out-
come in patients receiving intravenous (IV) recombinant tissue
plasminogen activator (rt-PA) compared to placebo at 3months,
the US Food and Drug Administration (FDA) approved IV rt-PA
for the treatment of ischemic stroke within 3 h from symptom
onset (NINDS, 1995). Recently, the time window for IV throm-
bolysis was further extended to 4.5 h following the ECASS 3 trial
which demonstrated beneﬁt in a more select group of patients
(Hacke et al., 2008). Following the ECASS 3 trial ﬁndings, the
European Stroke Organization endorsed IV thrombolysis in their
2009 Stroke Guidelines for ischemic stroke patients presenting
up to the 4.5-h time window. In the United States, many stroke
centers have adopted administration of IV rt-PA in this time win-
dow using similar entry criteria as the ECASS 3 trial (Davis and
Donnan, 2009).
Despite extension of the time window for acute stroke therapy,
IV thrombolysis presents numerous challenges; early recanaliza-
tion after IV rt-PA occurs in only 30–50% of patients, it has
less favorable results for proximal occlusions (del Zoppo et al.,
1992; NINDS, 1995; Lee et al., 2007), and re-occlusion is fre-
quent after IV rt-PA (Grotta et al., 2001; Alexandrov and Grotta,
2002). While many patients do not present in early time win-
dows (Kleindorfer et al., 2008), the number needed to treat (NNT)
to get one added favorable outcome increases from 2 during the
ﬁrst 90min to 7 within 3 h, and reaches 14 between 3 and 4.5 h
(Hacke et al., 2008).
Endovascular therapy includes intra-arterial (IA) throm-
bolytic therapy and mechanical thrombectomy. It is an alter-
native treatment for acute ischemic stroke in patients who are
ineligible for IV thrombolysis and who present beyond the
thrombolysis time window. It is also an option for patients
who do not improve after IV thrombolysis (Wolpert et al.,
1993). The main advantage of IA thrombolytic therapy is that
it allows direct delivery of a highly concentrated and locally
delivered thrombolytic drug to the thrombus within the end-
organ distribution, permitting lower total amounts of systemic
thrombolytics to achieve recanalization. The other advantage is
that mechanical thrombectomy may spare usage of a chemical
thrombolytic entirely. Disadvantages of IA approaches include
the need for a neurointerventional team, the requirement to
rapidly mobilize such a team, and the added time required to
obtain subselective IA access in order to reopen the occluded
vessel.
The principal goal of IA stroke therapy is to safely and rapidly
restore ﬂow. There are two components required to achieve
this goal: recanalizing the original or primary arterial occlusive
lesion (AOL) in order to reperfuse the distal arterial bed and
brain parenchyma (Tomsick, 2007). Successful recanalization has
been associated with improved outcomes (Rha and Saver, 2007;
Nogueira et al., 2009a). Three types of reperfusion strategies have
been proposed (Nogueira et al., 2009a):
1. recanalization or antegrade reperfusion
2. global reperfusion (ﬂow augmentation by maximizing col-
lateral circulation, or transarterial retrograde reperfusion),
and
3. transvenous retrograde reperfusion
Most endovascular therapies use recanalization or antegrade
reperfusion as the mechanism for restoration of ﬂow. In this
review, we will discuss available thrombolytic therapies and
endovascular recanalization techniques, beginning with chemi-
cal thrombolytic agents, followed by mechanical devices (Table 1),
and a review of ongoing trials (Table 2). While not all chemical
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Table 2 | Current randomized trials.
Goal n Current n NIH Time window (h) Randomization Primary outcome Start, end date
(April 2010)
IMS III 900 371 ≥10 3 IV t-PA vs 0.6mg/kg
IV t-PA and IA
mRS 3months 2006–2014
THRACE 480 Pending ≥10 3 IV t-PA vs 0.9mg/kg
IV t-PA and IA
mRS 3months 2010–2011
SYNTHESIS EXP >344 170 Open 4.5 IV t-PA vs IA t-PA up
to 0.9mg/kg (max
90mg)
mRS 0–1, 3months Feb 2008, Sept 2011
MR CLEAN 500 Pending ≥2 6 IA rt-PA+/or
mechanical vs no IA
mRS 90days Jan 2010, Jan 2015
MR RESCUE 120 77 ≥6 8 Standard vs IA with
MR perfusion
mRS 90days 2005
SENTIS 515 515 5–18 10 Standard vs aortic
balloon catheter
“neurological
improvement;” serious
adverse events 90 days
2008–2011
DAWN Pending Pending ≥10 Indeterminate Standard vs IA with
CT perfusion or MR
perfusion
mRS 90days 2009
SWIFT 200 Pending 8–30 8 Merci vs Solitaire
device
TIMI 2 or 3 ﬂow Jan 2010–Dec 2011
thrombolytic agents have beenusedor tested via IA routes, a review
of chemical thrombolytics is important in the grand spectrum of
acute ischemic stroke treatment.
INTRA-ARTERIAL AND/OR INTRAVENOUS CHEMICAL
THROMBOLYSIS
A number of agents have been used for thrombolytic treat-
ment of stroke including: streptokinase, urokinase, alteplase, pro-
urokinase, reteplase, tenecteplase, and desmoteplase. In principle,
these agents convert the proenzyme plasminogen to plasmin,
which when activated subsequently breaks down ﬁbrin into ﬁbrin
degradation products. The main advantage of IA over IV chemical
thrombolysis is that it allows direct delivery of drug to the throm-
bus, and compared to mechanical techniques it requires less vessel
instrumentation to reopen occluded arteries. Chemical throm-
bolysis also can work on distal clots, in M2, M3, and higher order
branches which may be inaccessible to most mechanical devices.
Despite very low systemic doses of these drugs when administered
IA, the occurrence of intracranial hemorrhage (ICH) is the most
feared complication. Of additional concern often a relatively long
interval can elapse between initiation of drug infusion and time to
vessel reopening, and such therapy failure is not uncommon.
First generation agents such as streptokinase and urokinase
(withdrawn from the market) are plasminogen activators and are
mainly of historical interest. Both agents have been tested in IV and
IA thrombolytic trials respectively. This class of drug is not ﬁbrin
speciﬁc, thus systemic hypoﬁbrinogenemia may occur. Streptoki-
nase is immunogenic and may lead to drug resistance, fever, and
allergic reactions. The rate of ICH is increased with streptokinase,
hence it is no longer used for IV or IA stroke therapy (Nogueira
et al., 2009a).
In contrast to ﬁrst generation agents, second generation agents,
such as alteplase and pro-urokinase are ﬁbrin speciﬁc and are
not antigenic. Alteplase or rt-PA has a similar proﬁle to native
plasminogen activator and acts by converting the proenzyme plas-
minogen to the active enzyme plasmin. The plasma half life of
alteplase is 4–6min, and the dose used for IA lysis can range
in practice from 1 to 60mg. One possibly concerning feature of
alteplase is that itmay have neurotoxic properties including activa-
tion of metalloproteinases, which may result in increased blood–
brain barrier permeability leading to ICH and edema (Nogueira
et al., 2009a). Pro-urokinase is a second generation agent which is
a precursor of urokinase and has a half life of 7min.
Third generation thrombolytics, such as reteplase and
tenecteplase, are modiﬁed forms of alteplase, have greater throm-
bolytic potency and longer half-lives compared to alteplase
(Nogueira et al., 2009b). Compared with the second generation
thrombolytics, reteplase does not bind as strongly with ﬁbrin. In a
phase I reteplase safety study, IA reteplase (0.5, 1, 1.5, 2 units) with
IV abciximab (platelet glycoprotein IIb/IIIa inhibitor) at a dose
of 0.25mg/kg bolus followed by 0.125μg/kg/min was adminis-
tered to acute ischemic stroke patients presenting between 3 and
6 h after symptom onset. The goal was to achieve higher rates of
recanalization with a medication combination using two different
mechanismsof action– IA reteplase to lyse ﬁbrin and IVabciximab
to prevent platelet aggregation. Of 20 patients in this study, one
symptomatic ICH was observed (1-unit tier); partial or complete
recanalization was observed in 13 of 20 (65%) patients (Qureshi
et al., 2006).
Compared to alteplase, tenecteplase has a longer half life
(17min), higher ﬁbrin speciﬁcity, and better resistance to plas-
minogen activator inhibitor-1 (Nogueira et al., 2009b). In a pilot
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study of patients presenting 3–6 h after ischemic stroke onset
with perfusion deﬁcit, 0.1mg/kg IV tenecteplase was given to 15
patients and compared with 29 patients treated with alteplase
(Parsons et al., 2009). The primary outcome was reperfusion as
assessed by interval reduction in the mean transit time lesion
(MTT) at 24 h on MRI perfusion imaging, in addition to major
vessel recanalization. Greater reperfusion volumes (mean 74 vs
44% for the alteplase control group) and major vessel recanaliza-
tion rates (10/15 tenecteplase vs 7/29 alteplase,p = 0.01)were seen.
Despite delayed time to treatment in the tenecteplase arm, more
tenecteplase patients had major neurologic improvement at 24 h
compared to patients treated with alteplase. Although the number
of stroke events was small, there were no parenchymal hematomas
in the tenecteplase patients.
There are additional new generation agents which include
desmoteplase, a genetically engineered version of the clot-
dissolving factor found in the saliva of the vampire bat desmodus
rotundus (Nogueira et al., 2009b). Desmoteplase is more selec-
tive for ﬁbrin-bound plasminogen than any other known plas-
minogen activator. In the Desmoteplase in Acute Ischemic Stroke
(DIAS) 2 trial, MR or CT perfusion imaging was used to ran-
domize 193 patients presenting within 3–9 h of symptom onset
to two evaluated doses of desmoteplase (90μg/g, 125μg/kg) or
a placebo arm. While the study did not show clinical beneﬁt,
and although the rates of symptomatic ICH were high (3.5%
for 90μg/kg desmoteplase, 4.5% for 125μg/kg desmoteplase, and
0% for placebo), a phase III randomized trial (DIAS 3) com-
paring IV desmoteplase 90μg/kg to placebo is currently ongo-
ing with a planned sample size of 320 patients triaged with
MRI or CT-angiography with vessel occlusion or high-grade
stenosis.
IA FIBRINOLYTIC RANDOMIZED TRIALS
The Prolyse in Acute Cerebral Thromboembolism (PROACT II)
trial is a landmark study that randomized patients presenting
within 6 h of a middle cerebral artery (MCA) occlusion to either
IA pro-urokinase or IV heparin. Higher rates of recanalization
were seen in the IA pro-urokinase treated cohort compared to the
IV heparin treated group (66 vs 18%) and 40% of IA patients
received an mRS score< 2 compared to 25% of controls (Furlan
et al., 1999). Risk of symptomatic hemorrhage was 11% in patients
receiving IA pro-urokinase compared to 3% of patients receiving
heparin alone (Kase et al., 2001). An absolute risk improvement of
15% or NNT of 7 was achieved. PROACT II was pivotal as the ﬁrst
randomized trial to demonstrate clinical efﬁcacy of IA therapies,
extending the therapeutic window to 6 h for acute ischemic stroke
patients. Although the success of PROACT II was insufﬁcient to
gain FDA approval for pro-urokinase, this led to a new era in IA
therapy for acute ischemic stroke patients.
TheMiddle CerebralArtery EmbolismLocal Fibrinolytic Inter-
vention Trial (MELT), a trial performed in Japan, randomized
patients presenting with MCA occlusion within 6 h of symptom
onset to either an IA urokinase (UK) arm or a conventional
treatment arm (Ogawa et al., 2007). The trial was stopped after
approval of rt-PA in Japan in October 2005. While the primary
endpoint of a modiﬁed Rankin Scale (mRS)≤ 1 did not reach
statistical signiﬁcance, secondary analyses suggested that IA UK
may offer increased likelihood of excellent functional outcomes at
90 days.
In patients with posterior circulation stroke presenting up to
24 h, theAustralianUrokinase Stroke Trial randomized 16 patients
to IA urokinase (increments of 100,000 IU to maximum dose of
1,000,000 IU) or control (no thrombolysis). All patients were anti-
coagulated acutely (5000 IU heparin IA followed by IV heparin to
target ptt of 60–80 for 2 days minimum), and then received oral
warfarin to target INR of 1.5–2.5 for 6months. There was some
imbalance between the groups, with more severe strokes occur-
ring in the IA arm. A good outcome was observed in four of eight
patients who received IA urokinase compared with one of eight
patients in the control group (MacLeod et al., 2005).
A meta-analysis comprising ﬁve randomized controlled trials
(PROACT I, II, MELT, Australian Urokinase Stroke Trial) found
that IA ﬁbrinolysis was associated with increased good clinical
outcomes deﬁned as mRS 0–2 (43 vs 28%; OR 2, 95% CI 1.3–
3.1; NNT 6.8) and excellent clinical outcomes deﬁned as mRS
0–1 (31 vs 18%; OR 2.1; 95% CI 1.3–3.5; NNT 7.7; Lee et al.,
2007). The rate of any radiological or symptomatic hemorrhage
was increased, although mortality was not higher.
INTRA-ARTERIAL MECHANICAL THROMBOLYSIS
Theprincipal goal ofmechanical thrombolysis is to restore cerebral
blood ﬂow by either removing or fragmenting obstructing throm-
bus. Advantages of fragmenting thrombus may include increasing
surface area exposure to thrombolysis (Levy et al., 2004; Nogueira
et al., 2009a). This approach may minimize or obviate the use
of chemical thrombolytics, thereby decreasing the risk of ICH
while extending the time window of intervention up to an 8-h
window for the anterior circulation. Faster recanalization may be
achieved with mechanical techniques as compared with infusion
lysis, especially with large clot burdens and with clots containing
large amounts of calcium and cholesterol (Halloran and Bekavac,
2004).Mechanical embolectomy is particularly helpful for patients
who are ineligible for chemical thrombolysis, patients who are
recently post-operative, coagulopathic, or who are presenting late
or with an unclear time of onset. The disadvantage of mechani-
cal devices is that almost all mechanical methods are less ﬂexible
than the smallest simple microcatheters through which throm-
bolytics can be introduced, especially since access pathways to
occlusive lesions are tortuous.Aggressive instrumentation can lead
to unfortunate complications such as dissection, perforation, ves-
sel rupture (Nguyen et al., 2008;Malik et al., 2010), and conversion
of distal emboli to more proximal larger-artery occlusions. Robust
clinical outcomes demonstrating beneﬁts of mechanical embolec-
tomy for acute ischemic stroke have yet to be generated from
randomized trials.
RETRIEVAL DEVICES
Several mechanical thrombectomy devices have been developed
over the last decades. The MERCI (Mechanical Embolus Removal
in Cerebral Ischemia) retriever (Concentric Medical, Moun-
tain View, CA, USA) was the ﬁrst stroke thrombectomy device
approved by the FDA in 2004 and increased the practicality of
mechanical thrombectomy beyond that formerly possible with
snaring. More than 10,000 MERCI devices have since been used
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worldwide (Concentric Medical, personal communication). The
MERCI device is an extremely ﬂexible corkscrew-shaped device
made of nitinol wire, designed to remove blood clots from the
brain in patients experiencing ischemic stroke. An 8- or 9-F bal-
loon guide catheter is placed in the internal carotid artery. The
retrieval device is introduced into a 2.4-F Merci microcatheter
and is advanced beyond the thrombus. The general principle of
its use is that upon retrieval of the device, the balloon in the guide
catheter is inﬂated to occlude the carotid artery with simultaneous
guide catheter aspiration to prevent distal embolization of throm-
bus with retrieval. Recently, a 4.3-F distal access catheter (DAC)
was added tonavigatemore distally and closer to the clot, and allow
for better leverage in clot retrieval. The ﬁrst generation MERCI X5
and X6 devices consisted of simple helical nitinol wire loops. The
second generation L4, L5, and L6 MERCI devices added ﬁlaments
to the helical nitinol coil to improve clot engagement and capture.
The third generation devices (V series) have variable tension in
the loops (Figure 1).
The Multi MERCI trial was an international, multicenter
prospective study that evaluated the combined safety of IV t-
PA and mechanical thrombectomy when used together. Favorable
FIGURE 1 | Merci RetrieverV 2.5 series (with permission, Concentrics
Medical).
clinical outcome (mRS 0–2) occurred in 36% of patients and mor-
tality was 34%. Both outcomes were related to vascular recanaliza-
tion. Symptomatic ICH and procedural complications occurred
in 10 and 5.5% of patients, respectively (Smith et al., 2008).
Although the MERCI device has had the largest impact to date
regarding sales volume, a number of other speciﬁcally directed
thrombectomy devices with various designs have also been devel-
oped. The Catch Thromboembolectomy System (Balt Extrusion,
Montmorency, France) is a self-expanding basket-like device with
a maximum diameter of 4mm, ﬁxed to a pusher wire. This device
has been tested and favorably compared with the MERCI device
in animal models.
The Phenox clot retriever (Phenox, Bochum, Germany) is a
ﬂexible nitinol/platinumcompound corewire resembling a bottle-
brush (Henkes et al., 2006). The wire compound ﬁrmly holds
perpendicularly-oriented polyamide microﬁlaments and carries
radiodense markers on its proximal and distal end. The contour of
this brush is trimmed in a conical shape with an increasing diam-
eter distally. Animal model studies comparing the MERCI, Catch,
and Phenox retriever system suggest that the Phenox retriever
may be superior in preventing distal embolization because it can
capture and ﬁlter the largest percentage of clot fragments (Liebig
et al., 2008). Preliminary case reports in patients suggest this device
holds promise as a useful supplement for thrombectomy (Henkes
et al., 2006).
TheAlligator Retriever (ChestnutMedical Technologies,Menlo
Park, CA, USA) is a four-pronged retrieval device on a stainless-
steel wire which resembles a clawlike hand, and which closes on
partial retraction into the tip of the carrying microcatheter. The
Alligator Retriever is FDA approved for the retrieval of intravas-
cular foreign bodies in the peripheral circulation and in the neu-
rovasculature. Its use has been reported in six patients with acute
MCAocclusion,with all patients achieving successful clot retrieval
and improvement in NIH stroke scale (Kerber et al., 2007). Once a
microcatheter is delivered to the thrombus, the retriever is pushed
a few millimeters beyond the catheter tip, allowing the jaws to
open. The microcatheter is then advanced to partially close the
jaws and trap the clot. The whole unit is then withdrawn along
with concomitant suction via a guide catheter in the internal
carotid artery.
The Trevo Device (Concentric Medical) is a new thrombus
retrieval system, involving a stentriever, a retrievable and non-
deployable stent-like device that is designed to act as retriever. This
device has received regulatory approval in Europe and Canada as
of February 2010. The Solitaire device is another retrievable stent-
on-a-wire (EV3) designed for neurovascular disease and may be
effective for acute ischemic stroke revascularization as a retriev-
able open-ended basket, but which has the additional feature of
controlled deployment permitting the Solitaire to be left in the
vessel as a conventional stent (Henkes et al., 2006).
ASPIRATION DEVICES
Several aspiration techniques and fragmentationdevices have been
developed for acute ischemic stroke treatment and include the
Penumbra System (Bose et al., 2008; Penumbra, Alameda, CA,
USA), Angiojet and manual aspiration. In contrast to retrieval
devices,which are deployeddistal to a thrombus for clot extraction,
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most of the aspiration techniques and fragmentation devices are
placed proximal to the thrombus. The advantage to aspiration
technique and devices is a lower rate of embolic events. The theory
of fragmentation assumes that fragmentation methods serve two
purposes; the ﬁrst, as mentioned earlier, is to increase the surface
area of the clot volume thereby permitting more effective throm-
bolysis, and the second purpose is to send the clot fragments into
the more distal circulation. This distal fragmentation recognizes
that leptomeningeal collateral supply is rich, serving a protective
and potentially redundant blood supply to more distal circula-
tions, and also recognizes the relatively small surface area of true
clinically eloquent cortex when compared with the total surface
area of the brain. Fragmentation approaches have evolved from
initial wire-maceration of clot to angioplasty of clot (thrombo-
plasty), to specialized methods for thrombofragmentation using
mechanical, ultrasound, and even low-energy laser-assistance.
Manual suction or aspiration with a syringe can be used in
the presence of a large vessel thrombus, such as in the internal
carotid artery or basilar artery. A 10 or 20 cc syringe can be placed
at the end of a catheter or large microcatheter. This technique
is inexpensive, rapid, but infrequently curative as solo technique.
However, it can be used as a bridge to using another device to
reopen the occluded vessel. A speciﬁc technical consideration is
selecting an appropriate microcatheter which is sufﬁciently rein-
forced to present collapse or coaptation once suction is applied, in
order to convey adequate suction to the tip of the microcatheter
for clot retrieval.
The Penumbra System (Penumbra, Alameda, CA, USA), was
FDA approved in January 2008, and designed to remove large
vessel thrombi in acute ischemic stroke patients via aspiration
and extraction. There are two main components of this system:
a reperfusion catheter and a specially designed microwire with a
distal olive known as a “separator” (Figure 2). The reperfusion
catheter is connected to a suction device, and as the separator is
gently pulled back and forth into the tip of the catheter there is
resultant fragmentation of the clot surface with fragment aspi-
ration into the catheter. There are now four different sizes of
microcatheter, consisting of 0.054′, 0.041′, 0.032′, and 0.026′ sized
to the vessel affected. Larger microcatheter sizes are much more
effective in generating higher suction. Both the Penumbra Pivotal
Stroke Trial (125 patients) and the Penumbra POST study (157
patients) evaluated the safety and effectiveness of the Penumbra
system in patients with stroke symptom onset within 8 h, and
NIHSS≥ 8 (Penumbra POST, 2009a,b). Mean NIHSS was above
16 in both studies. Complete or partial recanalization (TIMI 2–3)
was very high, achieved in over 80% of patients in both stud-
ies. Symptomatic ICH occurred in 11% in the Pivotal Trial and
6.4% in the POST study. In the POST study, good clinical out-
come deﬁned as mRS≤ 2 was achieved in 41% of patients and a
greater than 10 point improvement in the NIHSS was seen in 37%
of patients.
ANGIOPLASTY
Angioplasty and stenting may be particularly advantageous when
an acute vessel occlusion is related to local atherothrombotic dis-
ease. The diameter of the balloon should be slightly undersized in
reference to the diameter of the occluded vessel due to the fragility
of the intracranial vessels which distinctly and signiﬁcantly lack an
outer elastic lamina. Balloons commonly used include compliant
(Hyperglide, EV3, Irvine, CA, USA) and semicompliant balloons
(Gateway, Boston Scientiﬁc, Fremont, CA, USA). Balloon-assisted
thromboplasty can rapidly re-establish ﬂow, but its most feared
risk is vessel rupture. Several studies have shown the high efﬁcacy
of percutaneous transluminal angioplasty (PTA) with recanaliza-
tion rates of up to 90% (Ueda et al., 1998; Nakano et al., 2002;
Nogueira et al., 2009a). However, its results can also be disappoint-
ing for acute cerebral occlusions (Leary et al., 2003). Re-occlusion
is a common problem with balloon angioplasty, and adjunctive
thrombolytics or GPIIb/IIa inhibitors are often administered in
conjunction (Abou-Chebl et al., 2005).
STENTS
Initially, the use of balloon mounted stents for acute ischemic
stroke revascularization resulted in high morbidity and high rates
of ICH. Development of self-expandable stents for the intracra-
nial circulation gained increasing attention and usage with the
introduction of the Wingspan and Enterprise stents. The Enter-
prise stent (Cordis, Raynham, MA, USA) is a closed cell partially
retrievable stent, which was originally developed for adjunctive
FIGURE 2 | Penumbra microcatheter and separator system (with permission, Penumbra Inc.).
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use in intracranial aneurysm treatment, and which was subse-
quently used off-label for acute stroke therapy in several reports
(Levy et al., 2004; Kelly et al., 2008; Zaidat et al., 2008; Brekenfeld
et al., 2009; Mocco et al., 2010). A retrospective multicenter series
of 20 patients demonstrated revascularization in all patients (75%
with TIMI score of 3, 25% TIMI score of 2) and improvement
in NIH stroke scale in 75% of patients by four or more stroke
scale points (Mocco et al., 2010). An FDA-approved pilot study
of 20 patients evaluated the safety and efﬁcacy of primary stent
deployment for revascularization in acute stroke patients present-
ing within 8 h. Recanalization to TIMI 3 (60% of patients) or 2
(40% of patients) was achieved, while there was one (5%) symp-
tomatic and 2 (10%) asymptomatic ICH. The mRS was ≤1 in 9
of 20 patients at 1month. In the extracranial circulation, emer-
gent stenting for acute carotid occlusion was shown to have very
high recanalization rates, with rate of symptomatic ICH in 10%
(Jovin et al., 2005). Good outcome (mRS≤ 2) was achieved in
13/25 (52%) patients and mortality was 12%.
Despite the high success rates and fast times achieved for
recanalization with acute stenting, one of the limitations of acute
stenting remains the difﬁculty of navigating a stent through the
tortuous cerebrovascular anatomy, and as second concern is the
act of leaving behind a possibly unnecessarily implanted foreign
body in the patient. Retrievable and partially retrievable stents
such as Solitaire (EV3), the Trevo device (Concentric), and Enter-
prise (Cordis) may circumvent the latter problem. Thrombosis
of an acutely placed stent, obligating the patient to clopidogrel
and aspirin, and sometimes GPIIbIIIa inhibitors is another dis-
advantage of stents. These chemical agents can increase the risk
of hemorrhagic conversion of infarcts, or the risk of reperfusion
hemorrhage.
THE NEED FOR RANDOMIZED TRIALS
Despite the multitude of medications and devices developed for
acute ischemic stroke intervention, it is disappointing to recog-
nize that only two large randomized trials have been completed;
the PROACT I and II trials. The MELT trial was interrupted due
to approval of IV rt-PA in Japan. The resistance to planning and
initiating randomized trials lies in the neurointerventional com-
munity which questions whether the correct or optimal devices to
randomize patients are available at present, and whether the opti-
mal formula for patient selection using perfusion mapping have
been established. The ethical concerns voiced by proceduralists
who are asked to randomize patients is another signiﬁcant chal-
lenge. Is it ethical to randomize a young patient with a large MCA
stroke, large mismatch, and severe neurological deﬁcit? For such a
patient, a clinician may feel no clinical equipoise, and may exclude
this patient from a trial. However, a 72-year-old patient present-
ing at 4.5 h from stroke onset with right MCA stroke and NIHSS
of 14, ASPECTS score of 7, could be considered to have clinical
equipoise for randomization. Where equipoise exists, randomiz-
ing subjects to clinical trials is a rational and appropriate approach
(Tomsick, 2007).
There is an important need for randomized controlled trials
of acute stroke intervention to demonstrate the clinical beneﬁt
of our therapies. The most important measure for efﬁcacy of
any acute stroke treatment is not recanalization, but ultimately
is clinical outcome (Wechsler, 2006). Belief in our therapies is not
knowledge and conviction is not proof (Saver, 2006). Our initial
hypotheses have been proven wrong many times in our therapies
for cerebrovascular disease. Two examples of ﬂawed hypotheses
include the EC/IC bypass study which showed no beneﬁt from
performing MCA-STA bypass in patients with carotid occlusion,
and the WARRS study which showed absence of beneﬁt with war-
farin treatment compared to aspirin for secondary prevention
of stroke.
ONGOING AND FUTURE TRIALS
IMS III
The Interventional Management Stroke Trial III is a NIH
funded phase III randomized multicenter trial evaluating acute
ischemic stroke patients presenting within 3 h, comparing IV rt-
PA (0.9mg/kg) to reduced dose IV rt-PA (0.6mg/kg) followed by
IA therapy, with primary outcome measure of mRS at 3months
(Khatri et al., 2008). Despite the recent results of the ECASS 3
trial (Hacke et al., 2008), there time window for IV t-PA was study
inclusion was not extended to the 4.5-h window. As of April 2010,
371 of 900 patients have been recruited from 50 sites. The trial
plans to expand to Europe in the summer of 2010. The target for
trial completion is 2014 (Khatri, personal communication).
MR RESCUE
TheMagnetic Resonance andRecanalization of Stroke Clots Using
Embolectomy (MR RESCUE) study is a NIH funded trial eval-
uating whether mechanical embolectomy with the MERCI or
Penumbra device is superior to standard medical management
of acute ischemic stroke presenting within 8 h of stroke onset.
Patients treated with IV t-PA up to 4.5 h from symptom onset
with persistent vessel occlusion on post-treatment MRI may also
be included. The study aims to identify patients who may beneﬁt
from intervention using MRI perfusion imaging.
SYNTHESIS
SYNTHESIS is the ﬁrst randomized controlled trial comparing
IAT to IVT with alteplase in acute ischemic stroke within 4.5 h of
ischemic stroke onset. The study aims to evaluate the proportionof
independent survivors at 3 months. Preliminary data suggests that
rapid initiation of IA thrombolysis is a safe and feasible alternative
to IV thrombolysis in acute ischemic stroke (Ciccone et al., 2010).
The study began enrollment February 2008 and will end Septem-
ber 2011.As ofMarch2010 almost 50%of the target patient sample
has been recruited (goal is at least 172 patients per arm;A. Ciccone,
personal communication).
MR CLEAN
MR CLEAN is a multicenter randomized clinical trial of endovas-
cular treatment of acute ischemic stroke in the Netherlands. The
null hypothesis for this study is that endovascular treatment for
acute ischemic stroke with onset less than 6 h in patients with a
symptomatic proximal arterial occlusion leads to a similar distrib-
ution of functional outcomes as standard treatment. The primary
outcome studied is the modiﬁed Rankin scale at 90 days. A goal
of 500 patients is intended for recruitment, to be completed over
4 years. As of April 2010, the study awaits medical ethics approval
(Dippel, personal communication).
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RETRIEVE
Randomized Trial of Endovascular Treatment of Acute Ischemic
Stroke vs Medical Management was meant to be a multicenter
international prospective randomized controlled trial comparing
mechanical thrombectomy using the MERCI retriever with best
medical therapy (with or without IV thrombolysis) within 8 h
of stroke symptom onset. This study was funded by Concentric
Medical, but unfortunately has been placed on hold (Concen-
tric Medical, personal communication) for two reasons. The FDA
objected to including IA thrombolytic in the intervention arm
and four new national-sponsored randomized controlled trials in
Europe emerged, which would directly compete with RETRIEVE
(Concentrics, personal communication).
SWIFT
The Solitaire With the Intention for Thrombectomy (SWIFT)
Study is a randomized study which aims to demonstrate equiv-
alence of the SOLITAIRE™ FR Revascularization Device with the
MERCI Retrieval System in patients with acute ischemic stroke
presentingwithin 8 h of symptomonset andNIHSS 8–30. The pri-
mary objective is tomeasure arterial recanalization of the occluded
target vessel as measured by TIMI score of 2 or 3 without any
symptomatic ICH1.
DAWN
In patients with unclear-onset or wake-up strokes, preliminary
data suggest that IV or IA thrombolysis may be safely applied
based on MRI criteria (positive perfusion–diffusion mismatch
and absence of well-developed ﬂuid-attenuated inversion recovery
1www.clinicaltrials.gov
changes of acute diffusion lesions; Cho et al., 2008). The DWI and
CTP Assessment in the Triage of Wake-Up and Late Presenting
Strokes Undergoing Neurointervention trial is evaluating whether
MR perfusion or CTP based endovascular treatment in patients
with wake-up and late presenting strokes is as safe and effec-
tive as standard endovascular treatment performed within 8 h of
symptom onset (phase I) and leads to improved outcomes when
compared with best medical treatment (phase II, randomized
controlled trial; Nogueira et al., 2009a,2009b).
SENTIS
Partial aortic occlusionmay increase cerebral perfusion by increas-
ing cerebral collateral recruitment and salvage of penumbra tis-
sue. SENTIS (Safety and Efﬁcacy of NeuroFlo for Treatment of
Ischemic Stroke) was a randomized, controlled multicenter trial
designed to demonstrate the safety and efﬁcacy of the Neu-
roFlo treatment compared to standard medical care in ischemic
stroke patients presenting within 10 h of onset (Shuaib et al.,
2010). Preliminary results of the trial were presented at the 2010
International Stroke Conference and did not show beneﬁt to the
device.
CONCLUSION
Acute revascularization is associated with improved outcomes in
ischemic stroke patients. It is unclear which method of IA inter-
vention, if any, is ideal. Promising approaches in acute stroke
treatment are likely a combination of IV and endovascular revas-
cularization efforts, combining early treatment initiation with
direct clot manipulation and/or PTA/stenting (Gupta et al., 2006).
Further randomized studies comparing medical therapy, IV and
endovascular treatments are essential, and their implementation
will require the wide support and enthusiasm from the neurologic,
neuroradiologic and neurosurgical stroke communities.
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